18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes.

Journal Article (Journal Article;Review)

There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.

Full Text

Duke Authors

Cited Authors

  • Sheikhbahaei, S; Marcus, C; Subramaniam, RM

Published Date

  • April 2015

Published In

Volume / Issue

  • 10 / 2

Start / End Page

  • 125 - 145

PubMed ID

  • 25829083

Electronic International Standard Serial Number (EISSN)

  • 1879-9809

Digital Object Identifier (DOI)

  • 10.1016/j.cpet.2014.12.001


  • eng

Conference Location

  • United States